Ubs Group Ag Moon Lake Immunotherapeutics Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Group Ag holds 6,340 shares of MLTX stock, worth $329,933. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,340
Previous 3,267
94.06%
Holding current value
$329,933
Previous $143,000
123.08%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.13 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$442 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$155 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$144 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$121 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.92B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...